KIF18A and neoplasm: Notably, one inhibitor, GSC000190, appears to exhibit anti-cancer efficacy in tumours resistant to cisplatin and olaparib, highlighting the potential utility of targeting KIF18A in the context of therapy resistance, which is often associated with CIN [148].